Loading the company…
Loading the company…
Families: Thrombectomy, IVC filters & venous stents.
All companies · Product and company coverage
In the last ten years FDA made 6 decisions for Rapid Medical (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (2). The latest was on 2026-08-28.
| Family | Decisions on record |
|---|---|
| Thrombectomy, IVC filters & venous stents | 6 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-08-28 | 510(k) | K260617 | Tigertriever 13 Ultra Revascularization Device |
| 2026-03-12 | 510(k) | K253062 | Tigertriever 25 Revascularization Device |
| 2025-10-06 | 510(k) | K251603 | Tigertriever 17 Ultra Revascularization Device |
| 2023-04-17 | 510(k) | K230429 | Tigertriever 21 Revascularization Device, Tigertriever 17 Revascularization Device, Tigertriever 13 Revascularization Device |
| 2022-07-25 | 510(k) |
In 2025, Rapid Medical reported engagement with 117 surgeons and other clinicians in the states MedaRep covers, worth $295K in consulting, speaking, meals and travel for its device products, the most in New York ($71K to 9). Royalties are left out.
| K220808 |
| Tigertriever 13 Revascularization Device |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Rapid Medical.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($71K, 9 engaged), California ($49K, 11 engaged), Pennsylvania ($40K, 10 engaged), Iowa ($28K, 1 engaged), Georgia ($23K, 4 engaged).